Austin Tsai, MD
Family Medicine · Fayetteville, NYNPI 1235225756
Payments from drug & device makers
Across 162 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$312
- Lilly USA, LLC$289
- Novo Nordisk$236
- Otsuka America Pharmaceutical, Inc.$156
- Exact Sciences$152
- AbbVie$142
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,618100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $312 |
| Lilly USA, LLC | 20 | $289 |
| Novo Nordisk | 16 | $236 |
| Otsuka America Pharmaceutical, Inc. | 8 | $156 |
| Exact Sciences | 8 | $152 |
| AbbVie | 9 | $142 |
| Shield Therapeutics Inc | 7 | $134 |
| Amgen | 7 | $118 |
| Bayer | 5 | $95 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $92 |
| Paragon 28, Inc. | 1 | $71 |
| Novartis | 5 | $67 |
| Madrigal Pharmaceuticals | 2 | $61 |
| Teva Pharmaceuticals USA, Inc. | 5 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Boehringer Ingelheim | 4 | $58 |
| Astellas Pharma US Inc | 3 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Merck | 4 | $53 |
| GSK | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Gilead | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| AstraZeneca | 2 | $30 |
| Dexcom, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$2,618 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $73,549 |
| OzempicSemaglutide | 37 | $55,375 |
| EliquisApixaban | 57 | $43,565 |
| RybelsusSemaglutide | 14 | $28,422 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,607 |
| JanuviaSitagliptin Phosphate | 18 | $12,016 |
| Arnuity ElliptaFluticasone Furoate | 16 | $8,580 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,143 |
| Novolog FlexpenInsulin Aspart | 13 | $3,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $3,172 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,597 |
| Atorvastatin Calcium | 247 | $2,245 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,529 |
| Levothyroxine Sodium | 128 | $1,474 |
| Betamethasone Dipropionate | 27 | $1,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $236 | $83,79751 claims |
| Boehringer IngelheimJardiance | $58 | $73,54957 claims |
| PfizerEliquis | $312 | $43,56557 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Anoro Ellipta | $52 | $37,33058 claims |
| MerckJanuvia | $53 | $12,01618 claims |
| AbbVieSynthroid | $142 | $57217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Fayetteville
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.